| Aug 22 |
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
|
| Aug 22 |
Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD
|
| Aug 21 |
Lexicon to face FDA AdCom over diabetes therapy review
|
| Aug 21 |
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
|
| Aug 14 |
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
|
| Aug 13 |
Lexicon to cut 50% of workforce to focus on sotagliflozin
|
| Aug 13 |
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
|
| Aug 13 |
Lilly opens R&D hub; Ovid and Lexicon lay off staff
|
| Aug 7 |
Lexicon to present data on sotagliflozin for diabetes, kidney disease
|
| Aug 7 |
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
|
